Details of the Drug

General Information of Drug (ID: DMA8FS5)

• Drug Name: Dronedarone
• Synonyms: Multaq; Dronedarone [INN]; SR 33589; SR 33589B; Dronedarone (INN); Sanofi-Aventis brand of dronedarone; N-[2-butyl-3-[4-[3-(dibutylamino)propoxy]benzoyl]-1-benzofuran-5-yl]methanesulfonamide; N-(2-Butyl-3-(p-(3-(dibutylamino)propoxy)benzoyl)-5-benzofuranyl)methanesulfonamide; N-[2-butyl-3-{4-[3-(dibutylamino)propoxy]benzoyl}-1-benzofuran-5-yl]methanesulfonamide; N-(2-butyl-3-(4-(3-(dibutylamino)propoxy)benzoyl)-5-benzofuranyl)-methanesulfonamide

Indication

Disease Entry	ICD 11	Status	REF
Angina pectoris	BA40	Approved	[1]
Atrial fibrillation	BC81.3	Withdrawn from market	[1]

• Drug Type: Small molecular drug
• #Ro5 Violations (Lipinski): 3:
  Molecular Weight (mw); 556.8
  Logarithm of the Partition Coefficient (xlogp); 7.2
  Rotatable Bond Count (rotbonds); 18
  Hydrogen Bond Donor Count (hbonddonor); 1
  Hydrogen Bond Acceptor Count (hbondacc); 7
• ADMET Property:
  BDDCS Class: Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 2: low solubility and high permeability [2]
  Clearance: The clearance of drug is 130-150 L/h [3]
  Elimination: Following oral administration, about 84% of the labeled dose is excreted in feces and 6% is excreted in urine, mainly as metabolites [3]
  Half-life: The concentration or amount of drug in body reduced by one-half in 13 - 19 hours [3]
  Metabolism: The drug is metabolized via the hepatic [3]
  MRTD: The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 20.5266 micromolar/kg/day [4]
  Unbound Fraction: The unbound fraction of drug in plasma is 0.02% [5]
  Vd: The volume of distribution (Vd) of drug is 1200-1400 L [3]
  Water Solubility: The ability of drug to dissolve in water is measured as 0.5 mg/mL [2]
• Chemical Identifiers:
  Formula: C31H44N2O5S
  IUPAC Name: N-[2-butyl-3-[4-[3-(dibutylamino)propoxy]benzoyl]-1-benzofuran-5-yl]methanesulfonamide
  Canonical SMILES: CCCCC1=C(C2=C(O1)C=CC(=C2)NS(=O)(=O)C)C(=O)C3=CC=C(C=C3)OCCCN(CCCC)CCCC
  InChI: InChI=1S/C31H44N2O5S/c1-5-8-12-29-30(27-23-25(32-39(4,35)36)15-18-28(27)38-29)31(34)24-13-16-26(17-14-24)37-22-11-21-33(19-9-6-2)20-10-7-3/h13-18,23,32H,5-12,19-22H2,1-4H3
  InChIKey: ZQTNQVWKHCQYLQ-UHFFFAOYSA-N
• Cross-matching ID:
  PubChem CID: 208898
  ChEBI ID: CHEBI:50659
  CAS Number: 141626-36-0
  DrugBank ID: DB04855
  TTD ID: D05CPV
  VARIDT ID: DR00531
  INTEDE ID: DR0550
  ACDINA ID: D00218
• Repurposed Drugs (RPD): Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Potassium channel unspecific (KC)	TT1VOHK	NOUNIPROTAC	Inhibitor	[6]
Voltage-gated potassium channel Kv1.5 (KCNA5)	TTW0CMT	KCNA5_HUMAN	Blocker	[7]

Drug-Metabolizing Enzyme (DME)

DME Name	DME ID	UniProt ID	MOA	REF
Cytochrome P450 3A4 (CYP3A4) Main DME	DE4LYSA	CP3A4_HUMAN	Substrate	[8]
Cytochrome P450 2D6 (CYP2D6)	DECB0K3	CP2D6_HUMAN	Substrate	[9]
Cytochrome P450 3A5 (CYP3A5)	DEIBDNY	CP3A5_HUMAN	Substrate	[10]

Drug Off-Target (DOT)

DOT Name	DOT ID	UniProt ID	Interaction	REF
Caspase-3 (CASP3)	OTIJRBE7	CASP3_HUMAN	Gene/Protein Processing	[11]
Caspase-7 (CASP7)	OTAPJ040	CASP7_HUMAN	Gene/Protein Processing	[11]
Cyclin-dependent kinase 2 (CDK2)	OTB5DYYZ	CDK2_HUMAN	Gene/Protein Processing	[12]
Cyclin-dependent kinase 4 (CDK4)	OT7EP05T	CDK4_HUMAN	Gene/Protein Processing	[12]
Cyclin-dependent kinase 6 (CDK6)	OTR95N0X	CDK6_HUMAN	Gene/Protein Processing	[12]
Cytochrome P450 1A1 (CYP1A1)	OTE4EFH8	CP1A1_HUMAN	Regulation of Drug Effects	[12]
Cytochrome P450 1B1 (CYP1B1)	OTYXFLSD	CP1B1_HUMAN	Gene/Protein Processing	[13]
Cytochrome P450 2B6 (CYP2B6)	OTOYO4S7	CP2B6_HUMAN	Regulation of Drug Effects	[12]
Cytochrome P450 2C18 (CYP2C18)	OTY687L9	CP2CI_HUMAN	Regulation of Drug Effects	[12]
Cytochrome P450 2C19 (CYP2C19)	OTFMJYYE	CP2CJ_HUMAN	Regulation of Drug Effects	[12]

Molecular Expression Atlas of This Drug

• The Studied Disease: Angina pectoris
• ICD Disease Classification: BA40

Molecule Name	Molecule Type	Gene Name	p-value	Fold-Change	Z-score
Cytochrome P450 3A5 (CYP3A5)	DME	CYP3A5	5.82E-01	-6.00E-02	-2.69E-01
Cytochrome P450 2D6 (CYP2D6)	DME	CYP2D6	7.95E-01	-7.47E-02	-2.45E-01
Cytochrome P450 3A4 (CYP3A4)	DME	CYP3A4	9.85E-01	2.24E-02	7.33E-02

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Same Disease as Dronedarone

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Disease	REF
Ivabradine	DM0L594	Major	Increased risk of ventricular arrhythmias by the combination of Dronedarone and Ivabradine.	Angina pectoris [BA40]	[14]

Coadministration of a Drug Treating the Disease Different from Dronedarone (Comorbidity)

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Comorbidity	REF
Remdesivir	DMBFZ6L	Moderate	Increased risk of hepatotoxicity by the combination of Dronedarone and Remdesivir.	1D6YCoronavirus Disease 2019 [1D6YCoronavirus Disease 2019]	[15]
Midostaurin	DMI6E0R	Major	Increased risk of prolong QT interval by the combination of Dronedarone and Midostaurin.	Acute myeloid leukaemia [2A60]	[16]
Gilteritinib	DMTI0ZO	Major	Increased risk of prolong QT interval by the combination of Dronedarone and Gilteritinib.	Acute myeloid leukaemia [2A60]	[16]
Oliceridine	DM6MDCF	Major	Increased risk of prolong QT interval by the combination of Dronedarone and Oliceridine.	Acute pain [MG31]	[16]
Bedaquiline	DM3906J	Major	Increased risk of prolong QT interval by the combination of Dronedarone and Bedaquiline.	Antimicrobial drug resistance [MG50-MG52]	[16]
Levalbuterol	DM5YBO1	Moderate	Increased risk of ventricular arrhythmias by the combination of Dronedarone and Levalbuterol.	Asthma [CA23]	[17]
Retigabine	DMGNYIH	Major	Increased risk of prolong QT interval by the combination of Dronedarone and Retigabine.	Behcet disease [4A62]	[16]
Cariprazine	DMJYDVK	Moderate	Decreased metabolism of Dronedarone caused by Cariprazine mediated inhibition of CYP450 enzyme.	Bipolar disorder [6A60]	[18]
Pexidartinib	DMS2J0Z	Major	Increased risk of hepatotoxicity by the combination of Dronedarone and Pexidartinib.	Bone/articular cartilage neoplasm [2F7B]	[19]
Eribulin	DM1DX4Q	Major	Increased risk of prolong QT interval by the combination of Dronedarone and Eribulin.	Breast cancer [2C60-2C6Y]	[16]
HKI-272	DM6QOVN	Major	Decreased metabolism of Dronedarone caused by HKI-272 mediated inhibition of CYP450 enzyme.	Breast cancer [2C60-2C6Y]	[20]
LY2835219	DM93VBZ	Moderate	Decreased metabolism of Dronedarone caused by LY2835219 mediated inhibition of CYP450 enzyme.	Breast cancer [2C60-2C6Y]	[21]
Tucatinib	DMBESUA	Major	Decreased metabolism of Dronedarone caused by Tucatinib mediated inhibition of CYP450 enzyme.	Breast cancer [2C60-2C6Y]	[15]
Palbociclib	DMD7L94	Moderate	Decreased metabolism of Dronedarone caused by Palbociclib mediated inhibition of CYP450 enzyme.	Breast cancer [2C60-2C6Y]	[22]
Cabazitaxel	DMPAZHC	Moderate	Decreased metabolism of Dronedarone caused by Cabazitaxel mediated inhibition of CYP450 enzyme.	Breast cancer [2C60-2C6Y]	[23]
Bosutinib	DMTI8YE	Major	Decreased metabolism of Dronedarone caused by Bosutinib mediated inhibition of CYP450 enzyme.	Breast cancer [2C60-2C6Y]	[15]
Macitentan	DMP79A1	Moderate	Decreased metabolism of Dronedarone caused by Macitentan mediated inhibition of CYP450 enzyme.	Cardiovascular disease [BA00-BE2Z]	[24]
PF-04449913	DMSB068	Major	Increased risk of prolong QT interval by the combination of Dronedarone and PF-04449913.	Chronic myelomonocytic leukaemia [2A40]	[16]
Olodaterol	DM62B78	Moderate	Increased risk of prolong QT interval by the combination of Dronedarone and Olodaterol.	Chronic obstructive pulmonary disease [CA22]	[25]
Vilanterol	DMF5EK1	Moderate	Increased risk of ventricular arrhythmias by the combination of Dronedarone and Vilanterol.	Chronic obstructive pulmonary disease [CA22]	[17]
Indacaterol	DMQJHR7	Moderate	Increased risk of ventricular arrhythmias by the combination of Dronedarone and Indacaterol.	Chronic obstructive pulmonary disease [CA22]	[25]
Fidaxomicin	DMFP6MV	Minor	Decreased clearance of Dronedarone due to the transporter inhibition by Fidaxomicin.	Clostridium difficile enterocolitis [1A04]	[26]
Intedanib	DMSTA36	Moderate	Decreased metabolism of Dronedarone caused by Intedanib mediated inhibition of CYP450 enzyme.	Colorectal cancer [2B91]	[27]
Ulipristal	DMBNI20	Minor	Decreased metabolism of Dronedarone caused by Ulipristal mediated inhibition of CYP450 enzyme.	Contraceptive management [QA21]	[28]
Pasireotide	DMHM7JS	Major	Increased risk of prolong QT interval by the combination of Dronedarone and Pasireotide.	Cushing syndrome [5A70]	[16]
Osilodrostat	DMIJC9X	Major	Increased risk of prolong QT interval by the combination of Dronedarone and Osilodrostat.	Cushing syndrome [5A70]	[16]
Ivacaftor	DMZC1HS	Major	Decreased metabolism of Dronedarone caused by Ivacaftor mediated inhibition of CYP450 enzyme.	Cystic fibrosis [CA25]	[28]
MK-8228	DMOB58Q	Moderate	Decreased metabolism of Dronedarone caused by MK-8228 mediated inhibition of CYP450 enzyme.	Cytomegaloviral disease [1D82]	[29]
Rivaroxaban	DMQMBZ1	Moderate	Decreased metabolism of Dronedarone caused by Rivaroxaban mediated inhibition of CYP450 enzyme.	Deep vein thrombosis [BD71]	[15]
Vilazodone	DM4LECQ	Moderate	Decreased metabolism of Dronedarone caused by Vilazodone mediated inhibition of CYP450 enzyme.	Depression [6A70-6A7Z]	[30]
OPC-34712	DMHG57U	Major	Decreased metabolism of Dronedarone caused by OPC-34712 mediated inhibition of CYP450 enzyme.	Depression [6A70-6A7Z]	[31]
Polatuzumab vedotin	DMF6Y0L	Moderate	Decreased metabolism of Dronedarone caused by Polatuzumab vedotin mediated inhibition of CYP450 enzyme.	Diffuse large B-cell lymphoma [2A81]	[32]
Alvimopan	DMHR8KW	Moderate	Decreased clearance of Dronedarone due to the transporter inhibition by Alvimopan.	Digestive system disease [DE2Z]	[22]
Ingrezza	DMVPLNC	Major	Increased risk of prolong QT interval by the combination of Dronedarone and Ingrezza.	Dystonic disorder [8A02]	[16]
Cenobamate	DM8KLU9	Moderate	Increased metabolism of Dronedarone caused by Cenobamate mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[22]
Stiripentol	DMMSDOY	Moderate	Decreased metabolism of Dronedarone caused by Stiripentol mediated inhibition of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[28]
Rufinamide	DMWE60C	Moderate	Increased metabolism of Dronedarone caused by Rufinamide mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[22]
Eslicarbazepine	DMZREFQ	Moderate	Increased metabolism of Dronedarone caused by Eslicarbazepine mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[22]
Cannabidiol	DM0659E	Minor	Decreased metabolism of Dronedarone caused by Cannabidiol mediated inhibition of CYP450 enzyme.	Epileptic encephalopathy [8A62]	[28]
Bay 80-6946	DMLOS5R	Moderate	Decreased metabolism of Dronedarone caused by Bay 80-6946 mediated inhibition of CYP450 enzyme.	Follicular lymphoma [2A80]	[33]
Tazemetostat	DMWP1BH	Major	Decreased metabolism of Dronedarone caused by Tazemetostat mediated inhibition of CYP450 enzyme.	Follicular lymphoma [2A80]	[34]
Mirabegron	DMS1GYT	Minor	Decreased metabolism of Dronedarone caused by Mirabegron mediated inhibition of CYP450 enzyme.	Functional bladder disorder [GC50]	[35]
Ripretinib	DM958QB	Moderate	Decreased metabolism of Dronedarone caused by Ripretinib mediated inhibition of CYP450 enzyme.	Gastrointestinal stromal tumour [2B5B]	[15]
Avapritinib	DMK2GZX	Major	Decreased metabolism of Dronedarone caused by Avapritinib mediated inhibition of CYP450 enzyme.	Gastrointestinal stromal tumour [2B5B]	[28]
Levobetaxolol	DMSREPX	Moderate	Increased risk of bradycardia by the combination of Dronedarone and Levobetaxolol.	Glaucoma [9C61]	[22]
Boceprevir	DMBSHMF	Major	Decreased metabolism of Dronedarone caused by Boceprevir mediated inhibition of CYP450 enzyme.	Hepatitis virus infection [1E50-1E51]	[15]
Telaprevir	DMMRV29	Major	Decreased metabolism of Dronedarone caused by Telaprevir mediated inhibition of CYP450 enzyme.	Hepatitis virus infection [1E50-1E51]	[15]
Daclatasvir	DMSFK9V	Moderate	Decreased metabolism of Dronedarone caused by Daclatasvir mediated inhibition of CYP450 enzyme.	Hepatitis virus infection [1E50-1E51]	[15]
Brentuximab vedotin	DMWLC57	Moderate	Increased risk of hepatotoxicity by the combination of Dronedarone and Brentuximab vedotin.	Hodgkin lymphoma [2B30]	[36]
MK-1439	DM215WE	Minor	Decreased metabolism of Dronedarone caused by MK-1439 mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[37]
Fostemsavir	DM50ILT	Major	Increased risk of prolong QT interval by the combination of Dronedarone and Fostemsavir.	Human immunodeficiency virus disease [1C60-1C62]	[16]
Cobicistat	DM6L4H2	Major	Decreased metabolism of Dronedarone caused by Cobicistat mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[15]
Dolutegravir	DMCZGRE	Minor	Decreased metabolism of Dronedarone caused by Dolutegravir mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[38]
Etravirine	DMGV8QU	Moderate	Increased metabolism of Dronedarone caused by Etravirine mediated induction of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[22]
Rilpivirine	DMJ0QOW	Major	Increased risk of prolong QT interval by the combination of Dronedarone and Rilpivirine.	Human immunodeficiency virus disease [1C60-1C62]	[16]
Mipomersen	DMGSRN1	Major	Increased risk of hepatotoxicity by the combination of Dronedarone and Mipomersen.	Hyper-lipoproteinaemia [5C80]	[39]
Teriflunomide	DMQ2FKJ	Major	Increased risk of hepatotoxicity by the combination of Dronedarone and Teriflunomide.	Hyper-lipoproteinaemia [5C80]	[16]
BMS-201038	DMQTAGO	Major	Decreased metabolism of Dronedarone caused by BMS-201038 mediated inhibition of CYP450 enzyme.	Hyper-lipoproteinaemia [5C80]	[15]
Aliskiren	DM1BV7W	Moderate	Decreased metabolism of Dronedarone caused by Aliskiren mediated inhibition of CYP450 enzyme.	Hypertension [BA00-BA04]	[16]
Tolvaptan	DMIWFRL	Moderate	Decreased metabolism of Dronedarone caused by Tolvaptan mediated inhibition of CYP450 enzyme.	Hypo-osmolality/hyponatraemia [5C72]	[40]
Pirfenidone	DM6VZFQ	Moderate	Decreased metabolism of Dronedarone caused by Pirfenidone mediated inhibition of CYP450 enzyme.	Idiopathic interstitial pneumonitis [CB03]	[28]
Berotralstat	DMWA2DZ	Major	Decreased clearance of Dronedarone due to the transporter inhibition by Berotralstat.	Innate/adaptive immunodeficiency [4A00]	[41]
Suvorexant	DM0E6S3	Major	Decreased metabolism of Dronedarone caused by Suvorexant mediated inhibition of CYP450 enzyme.	Insomnia [7A00-7A0Z]	[42]
Tasimelteon	DMLOQ1V	Moderate	Decreased metabolism of Dronedarone caused by Tasimelteon mediated inhibition of CYP450 enzyme.	Insomnia [7A00-7A0Z]	[43]
ITI-007	DMUQ1DO	Major	Decreased metabolism of Dronedarone caused by ITI-007 mediated inhibition of CYP450 enzyme.	Insomnia [7A00-7A0Z]	[44]
Polyethylene glycol	DM4I1JP	Major	Increased risk of ventricular arrhythmias by the combination of Dronedarone and Polyethylene glycol.	Irritable bowel syndrome [DD91]	[45]
Naloxegol	DML0B41	Major	Decreased metabolism of Dronedarone caused by Naloxegol mediated inhibition of CYP450 enzyme.	Large intestine motility disorder [DB32]	[28]
Pemigatinib	DM819JF	Major	Decreased metabolism of Dronedarone caused by Pemigatinib mediated inhibition of CYP450 enzyme.	Liver cancer [2C12]	[28]
Crizotinib	DM4F29C	Major	Increased risk of prolong QT interval by the combination of Dronedarone and Crizotinib.	Lung cancer [2C25]	[16]
Lurbinectedin	DMEFRTZ	Major	Decreased metabolism of Dronedarone caused by Lurbinectedin mediated inhibition of CYP450 enzyme.	Lung cancer [2C25]	[46]
Osimertinib	DMRJLAT	Major	Increased risk of prolong QT interval by the combination of Dronedarone and Osimertinib.	Lung cancer [2C25]	[16]
Pralsetinib	DMWU0I2	Moderate	Decreased metabolism of Dronedarone caused by Pralsetinib mediated inhibition of CYP450 enzyme.	Lung cancer [2C25]	[47]
Capmatinib	DMYCXKL	Moderate	Decreased metabolism of Dronedarone caused by Capmatinib mediated inhibition of CYP450 enzyme.	Lung cancer [2C25]	[48]
Selpercatinib	DMZR15V	Major	Increased risk of prolong QT interval by the combination of Dronedarone and Selpercatinib.	Lung cancer [2C25]	[16]
Lumefantrine	DM29GAD	Major	Increased risk of prolong QT interval by the combination of Dronedarone and Lumefantrine.	Malaria [1F40-1F45]	[16]
Artesunate	DMR27C8	Moderate	Decreased clearance of Dronedarone due to the transporter inhibition by Artesunate.	Malaria [1F40-1F45]	[22]
Inotuzumab ozogamicin	DMAC130	Major	Increased risk of prolong QT interval by the combination of Dronedarone and Inotuzumab ozogamicin.	Malignant haematopoietic neoplasm [2B33]	[16]
Idelalisib	DM602WT	Major	Decreased metabolism of Dronedarone caused by Idelalisib mediated inhibition of CYP450 enzyme.	Mature B-cell leukaemia [2A82]	[15]
GDC-0199	DMH0QKA	Major	Decreased metabolism of Dronedarone caused by GDC-0199 mediated inhibition of CYP450 enzyme.	Mature B-cell leukaemia [2A82]	[15]
IPI-145	DMWA24P	Moderate	Decreased metabolism of Dronedarone caused by IPI-145 mediated inhibition of CYP450 enzyme.	Mature B-cell leukaemia [2A82]	[22]
Acalabrutinib	DM7GCVW	Major	Decreased metabolism of Dronedarone caused by Acalabrutinib mediated inhibition of CYP450 enzyme.	Mature B-cell lymphoma [2A85]	[49]
Ibrutinib	DMHZCPO	Major	Decreased metabolism of Dronedarone caused by Ibrutinib mediated inhibition of CYP450 enzyme.	Mature B-cell lymphoma [2A85]	[50]
Ponatinib	DMYGJQO	Moderate	Decreased metabolism of Dronedarone caused by Ponatinib mediated inhibition of CYP450 enzyme.	Mature B-cell lymphoma [2A85]	[51]
Arry-162	DM1P6FR	Moderate	Decreased clearance of Dronedarone due to the transporter inhibition by Arry-162.	Melanoma [2C30]	[15]
Vemurafenib	DM62UG5	Major	Increased risk of prolong QT interval by the combination of Dronedarone and Vemurafenib.	Melanoma [2C30]	[16]
Selumetinib	DMC7W6R	Major	Decreased metabolism of Dronedarone caused by Selumetinib mediated inhibition of CYP450 enzyme.	Melanoma [2C30]	[52]
Dabrafenib	DMX6OE3	Moderate	Increased metabolism of Dronedarone caused by Dabrafenib mediated induction of CYP450 enzyme.	Melanoma [2C30]	[28]
Ubrogepant	DM749I3	Moderate	Decreased metabolism of Dronedarone caused by Ubrogepant mediated inhibition of CYP450 enzyme.	Migraine [8A80]	[53]
Rimegepant	DMHOAUG	Moderate	Decreased metabolism of Dronedarone caused by Rimegepant mediated inhibition of CYP450 enzyme.	Migraine [8A80]	[54]
Flibanserin	DM70DTN	Major	Decreased metabolism of Dronedarone caused by Flibanserin mediated inhibition of CYP450 enzyme.	Mood disorder [6A60-6E23]	[55]
Panobinostat	DM58WKG	Major	Increased risk of prolong QT interval by the combination of Dronedarone and Panobinostat.	Multiple myeloma [2A83]	[16]
Siponimod	DM2R86O	Major	Increased risk of ventricular arrhythmias by the combination of Dronedarone and Siponimod.	Multiple sclerosis [8A40]	[15]
Fingolimod	DM5JVAN	Major	Increased risk of ventricular arrhythmias by the combination of Dronedarone and Fingolimod.	Multiple sclerosis [8A40]	[16]
Ozanimod	DMT6AM2	Major	Increased risk of prolong QT interval by the combination of Dronedarone and Ozanimod.	Multiple sclerosis [8A40]	[16]
Deflazacort	DMV0RNS	Major	Decreased metabolism of Dronedarone caused by Deflazacort mediated inhibition of CYP450 enzyme.	Muscular dystrophy [8C70]	[28]
Romidepsin	DMT5GNL	Major	Increased risk of prolong QT interval by the combination of Dronedarone and Romidepsin.	Mycosis fungoides [2B01]	[16]
Fedratinib	DM4ZBK6	Moderate	Decreased metabolism of Dronedarone caused by Fedratinib mediated inhibition of CYP450 enzyme.	Myeloproliferative neoplasm [2A20]	[22]
Nilotinib	DM7HXWT	Major	Increased risk of prolong QT interval by the combination of Dronedarone and Nilotinib.	Myeloproliferative neoplasm [2A20]	[16]
Ruxolitinib	DM7Q98D	Minor	Decreased metabolism of Dronedarone caused by Ruxolitinib mediated inhibition of CYP450 enzyme.	Myeloproliferative neoplasm [2A20]	[28]
Entrectinib	DMMPTLH	Major	Increased risk of prolong QT interval by the combination of Dronedarone and Entrectinib.	Non-small cell lung cancer [2C25]	[16]
Lofexidine	DM1WXA6	Major	Increased risk of prolong QT interval by the combination of Dronedarone and Lofexidine.	Opioid use disorder [6C43]	[16]
S-297995	DM26IH8	Moderate	Decreased metabolism of Dronedarone caused by S-297995 mediated inhibition of CYP450 enzyme.	Opioid use disorder [6C43]	[28]
Olaparib	DM8QB1D	Major	Decreased metabolism of Dronedarone caused by Olaparib mediated inhibition of CYP450 enzyme.	Ovarian cancer [2C73]	[15]
Rucaparib	DM9PVX8	Major	Increased risk of prolong QT interval by the combination of Dronedarone and Rucaparib.	Ovarian cancer [2C73]	[16]
MK-4827	DMLYGH4	Moderate	Decreased clearance of Dronedarone due to the transporter inhibition by MK-4827.	Ovarian cancer [2C73]	[56]
Triclabendazole	DMPWGBR	Major	Increased risk of prolong QT interval by the combination of Dronedarone and Triclabendazole.	Parasitic worm infestation [1F90]	[16]
Pimavanserin	DMR7IVC	Major	Increased risk of prolong QT interval by the combination of Dronedarone and Pimavanserin.	Parkinsonism [8A00]	[16]
Abametapir	DM2RX0I	Moderate	Decreased metabolism of Dronedarone caused by Abametapir mediated inhibition of CYP450 enzyme.	Pediculosis [1G00]	[57]
Macimorelin	DMQYJIR	Major	Increased risk of prolong QT interval by the combination of Dronedarone and Macimorelin.	Pituitary gland disorder [5A60-5A61]	[58]
Lefamulin	DME6G97	Major	Increased risk of prolong QT interval by the combination of Dronedarone and Lefamulin.	Pneumonia [CA40]	[16]
Lonafarnib	DMGM2Z6	Major	Decreased metabolism of Dronedarone caused by Lonafarnib mediated inhibition of CYP450 enzyme.	Premature ageing appearance [LD2B]	[15]
Degarelix	DM3O8QY	Major	Increased risk of prolong QT interval by the combination of Dronedarone and Degarelix.	Prostate cancer [2C82]	[16]
ABIRATERONE	DM8V75C	Major	Increased risk of prolong QT interval by the combination of Dronedarone and ABIRATERONE.	Prostate cancer [2C82]	[16]
Enzalutamide	DMGL19D	Major	Increased risk of prolong QT interval by the combination of Dronedarone and Enzalutamide.	Prostate cancer [2C82]	[16]
Relugolix	DMK7IWL	Major	Increased risk of prolong QT interval by the combination of Dronedarone and Relugolix.	Prostate cancer [2C82]	[16]
Darolutamide	DMV7YFT	Minor	Decreased metabolism of Dronedarone caused by Darolutamide mediated inhibition of CYP450 enzyme.	Prostate cancer [2C82]	[59]
Silodosin	DMJSBT6	Moderate	Decreased clearance of Dronedarone due to the transporter inhibition by Silodosin.	Prostate hyperplasia [GA90]	[60]
Ambrisentan	DMD1QXW	Moderate	Decreased clearance of Dronedarone due to the transporter inhibition by Ambrisentan.	Pulmonary hypertension [BB01]	[22]
Axitinib	DMGVH6N	Moderate	Decreased metabolism of Dronedarone caused by Axitinib mediated inhibition of CYP450 enzyme.	Renal cell carcinoma [2C90]	[28]
Temsirolimus	DMS104F	Moderate	Decreased metabolism of Dronedarone caused by Temsirolimus mediated inhibition of CYP450 enzyme.	Renal cell carcinoma [2C90]	[61]
Upadacitinib	DM32B5U	Moderate	Decreased metabolism of Dronedarone caused by Upadacitinib mediated inhibition of CYP450 enzyme.	Rheumatoid arthritis [FA20]	[62]
Tofacitinib	DMBS370	Moderate	Decreased metabolism of Dronedarone caused by Tofacitinib mediated inhibition of CYP450 enzyme.	Rheumatoid arthritis [FA20]	[15]
Iloperidone	DM6AUFY	Major	Increased risk of prolong QT interval by the combination of Dronedarone and Iloperidone.	Schizophrenia [6A20]	[16]
Amisulpride	DMSJVAM	Major	Increased risk of prolong QT interval by the combination of Dronedarone and Amisulpride.	Schizophrenia [6A20]	[16]
Asenapine	DMSQZE2	Major	Increased risk of prolong QT interval by the combination of Dronedarone and Asenapine.	Schizophrenia [6A20]	[16]
Avanafil	DM75CXN	Major	Decreased metabolism of Dronedarone caused by Avanafil mediated inhibition of CYP450 enzyme.	Sexual dysfunction [HA00-HA01]	[63]
Voxelotor	DMCS6M5	Moderate	Decreased metabolism of Dronedarone caused by Voxelotor mediated inhibition of CYP450 enzyme.	Sickle-cell disorder [3A51]	[22]
LDE225	DMM9F25	Major	Decreased metabolism of Dronedarone caused by LDE225 mediated inhibition of CYP450 enzyme.	Skin cancer [2C30-2C37]	[64]
Telotristat ethyl	DMDIYFZ	Moderate	Increased metabolism of Dronedarone caused by Telotristat ethyl mediated induction of CYP450 enzyme.	Small intestine developmental anomaly [DA90]	[28]
Larotrectinib	DM26CQR	Moderate	Decreased metabolism of Dronedarone caused by Larotrectinib mediated inhibition of CYP450 enzyme.	Solid tumour/cancer [2A00-2F9Z]	[22]
Trabectedin	DMG3Y89	Moderate	Increased risk of hepatotoxicity by the combination of Dronedarone and Trabectedin.	Solid tumour/cancer [2A00-2F9Z]	[28]
Armodafinil	DMGB035	Moderate	Increased metabolism of Dronedarone caused by Armodafinil mediated induction of CYP450 enzyme.	Solid tumour/cancer [2A00-2F9Z]	[22]
LEE011	DMMX75K	Major	Increased risk of prolong QT interval by the combination of Dronedarone and LEE011.	Solid tumour/cancer [2A00-2F9Z]	[16]
Vandetanib	DMRICNP	Major	Increased risk of prolong QT interval by the combination of Dronedarone and Vandetanib.	Solid tumour/cancer [2A00-2F9Z]	[16]
Triptorelin	DMTK4LS	Major	Increased risk of prolong QT interval by the combination of Dronedarone and Triptorelin.	Solid tumour/cancer [2A00-2F9Z]	[16]
Pitolisant	DM8RFNJ	Major	Increased risk of prolong QT interval by the combination of Dronedarone and Pitolisant.	Somnolence [MG42]	[16]
Telavancin	DM58VQX	Major	Increased risk of prolong QT interval by the combination of Dronedarone and Telavancin.	Staphylococcal/streptococcal disease [1B5Y]	[16]
Pomalidomide	DMTGBAX	Moderate	Decreased clearance of Dronedarone due to the transporter inhibition by Pomalidomide.	Systemic sclerosis [4A42]	[15]
Lusutrombopag	DMH6IKO	Moderate	Decreased clearance of Dronedarone due to the transporter inhibition by Lusutrombopag.	Thrombocytopenia [3B64]	[65]
Apixaban	DM89JLN	Moderate	Decreased metabolism of Dronedarone caused by Apixaban mediated inhibition of CYP450 enzyme.	Thrombosis [DB61-GB90]	[28]
Brilinta	DMBR01X	Moderate	Decreased metabolism of Dronedarone caused by Brilinta mediated inhibition of CYP450 enzyme.	Thrombosis [DB61-GB90]	[28]
Lenvatinib	DMB1IU4	Major	Increased risk of prolong QT interval by the combination of Dronedarone and Lenvatinib.	Thyroid cancer [2D10]	[16]
Cabozantinib	DMIYDT4	Major	Increased risk of prolong QT interval by the combination of Dronedarone and Cabozantinib.	Thyroid cancer [2D10]	[16]
Saxagliptin	DMGXENV	Moderate	Decreased metabolism of Dronedarone caused by Saxagliptin mediated inhibition of CYP450 enzyme.	Type 2 diabetes mellitus [5A11]	[28]
Elagolix	DMB2C0E	Moderate	Increased metabolism of Dronedarone caused by Elagolix mediated induction of CYP450 enzyme.	Uterine fibroid [2E86]	[22]
Fluticasone	DMGCSVF	Moderate	Decreased metabolism of Dronedarone caused by Fluticasone mediated inhibition of CYP450 enzyme.	Vasomotor/allergic rhinitis [CA08]	[15]

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG

DIG Name	DIG ID	PubChem CID	Functional Classification
Crospovidone	E00626	Not Available	Disintegrant
Hypromellose	E00634	Not Available	Coating agent
Lactose monohydrate	E00393	104938	Binding agent; Diluent; Dry powder inhaler carrier; Lyophilization aid
Magnesium stearate	E00208	11177	lubricant
Poloxamer 407	E00646	Not Available	Emulsifying agent; Solubilizing agent; Surfactant
Polyethylene glycol 6000	E00655	Not Available	Coating agent; Diluent; Ointment base; Plasticizing agent; Solvent; Suppository base; lubricant
Silicon dioxide	E00670	Not Available	Anticaking agent; Opacifying agent; Viscosity-controlling agent
Titanium dioxide	E00322	26042	Coating agent; Colorant; Opacifying agent
Hydrophobic colloidal silica	E00285	24261	Anticaking agent; Emulsion stabilizing agent; Glidant; Suspending agent; Viscosity-controlling agent
Pregelatinized starch	E00674	Not Available	Binding agent; Diluent; Disintegrant

Pharmaceutical Formulation

Formulation Name	Drug Dosage	Dosage Form	Route
Dronedarone Hydrochloride eq 400mg base tablet	eq 400mg base	Tablet	Oral
Dronedarone 400 mg tablet	400 mg	Oral Tablet	Oral

Jump to Detail Pharmaceutical Formulation Page of This Drug

References

• [1] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7465).
• [2] BDDCS applied to over 900 drugs
• [3] FDA Approved Drug Products: Multaq (dronedarone) oral tablets
• [4] Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
• [5] Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
• [6] Antibodies and venom peptides: new modalities for ion channels. Nat Rev Drug Discov. 2019 May;18(5):339-357.
• [7] New antiarrhythmic agents for atrial fibrillation and atrial flutter. Expert Opin Emerg Drugs. 2005 May;10(2):311-22.
• [8] Drug safety evaluation of dronedarone in atrial fibrillation. Expert Opin Drug Saf. 2012 Nov;11(6):1023-45.
• [9] Effect of dronedarone on the pharmacokinetics of carvedilol following oral administration to rats. Eur J Pharm Sci. 2018 Jan 1;111:13-19.
• [10] Inactivation of human cytochrome P450 3A4 and 3A5 by dronedarone and N-desbutyl dronedarone. Mol Pharmacol. 2016 Jan;89(1):1-13.
• [11] Mechanisms of hepatocellular toxicity associated with dronedarone--a comparison to amiodarone. Toxicol Sci. 2013 Feb;131(2):480-90. doi: 10.1093/toxsci/kfs298. Epub 2012 Nov 7.
• [12] The role of hepatic cytochrome P450s in the cytotoxicity of dronedarone. Arch Toxicol. 2018 Jun;92(6):1969-1981. doi: 10.1007/s00204-018-2196-x. Epub 2018 Apr 3.
• [13] Association of CYP1A1 and CYP1B1 inhibition in in vitro assays with drug-induced liver injury. J Toxicol Sci. 2021;46(4):167-176. doi: 10.2131/jts.46.167.
• [14] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT "Recommendations for the use of medications with continuous enteral nutrition." Am J Health Syst Pharm 66 (2009): 1438-67. [PMID: 19667002]
• [15] Cerner Multum, Inc. "Australian Product Information.".
• [16] Canadian Pharmacists Association.
• [17] Product Information. Arcapta Neohaler (indacaterol). Novartis Pharmaceuticals, East Hanover, NJ.
• [18] Product Information. Vraylar (cariprazine). Actavis Pharma, Inc., Parsippany, NJ.
• [19] Product Information. Turalio (pexidartinib). Daiichi Sankyo, Inc., Parsippany, NJ.
• [20] Abbas R, Hug BA, Leister C, Burns J, Sonnichsen D "Pharmacokinetics of oral neratinib during co-administration of ketoconazole in healthy subjects." Br J Clin Pharmacol 71 (2011): 522-7. [PMID: 21395644]
• [21] Product Information. Verzenio (abemaciclib). Lilly, Eli and Company, Indianapolis, IN.
• [22] Product Information. Multaq (dronedarone). sanofi-aventis , Bridgewater, NJ.
• [23] Product Information. Jevtana (cabazitaxel). sanofi-aventis , Bridgewater, NJ.
• [24] Product Information. Opsumit (macitentan). Actelion Pharmaceuticals US Inc, South San Francisco, CA.
• [25] Bengtsson B, Fagerstrom PO "Extrapulmonary effects of terbutaline during prolonged administration." Clin Pharmacol Ther 31 (1982): 726-32. [PMID: 7042176]
• [26] Product Information. Dificid (fidaxomicin). Optimer Pharmaceuticals, San Diego, CA.
• [27] Product Information. Ofev (nintedanib). Boehringer Ingelheim, Ridgefield, CT.
• [28] Cerner Multum, Inc. "UK Summary of Product Characteristics.".
• [29] Product Information. Prevymis (letermovir). Merck & Company Inc, Whitehouse Station, NJ.
• [30] Product Information. Viibryd (vilazodone). Trovis Pharmaceuticals LLC, New Haven, CT.
• [31] Product Information. Rexulti (brexpiprazole). Otsuka American Pharmaceuticals Inc, Rockville, MD.
• [32] Product Information. Polivy (polatuzumab vedotin). Genentech, South San Francisco, CA.
• [33] Product Information. Aliqopa (copanlisib). Bayer Pharmaceutical Inc, West Haven, CT.
• [34] Product Information. Tazverik (tazemetostat). Epizyme, Inc, Cambridge, MA.
• [35] Product Information. Myrbetriq (mirabegron). Astellas Pharma US, Inc, Deerfield, IL.
• [36] Product Information. VFEND (voriconazole). Pfizer U.S. Pharmaceuticals, New York, NY.
• [37] Product Information. Pifeltro (doravirine). Merck & Company Inc, Whitehouse Station, NJ.
• [38] Product Information. Tivicay (dolutegravir). ViiV Healthcare, Research Triangle Park, NC.
• [39] Product Information. Kynamro (mipomersen). Genzyme Corporation, Cambridge, MA.
• [40] Product Information. Samsca (tolvaptan). Otsuka American Pharmaceuticals Inc, Rockville, MD.
• [41] Product Information. Orladeyo (berotralstat). BioCryst Pharmaceuticals Inc, Durham, NC.
• [42] Product Information. Belsomra (suvorexant). Merck & Company Inc, Whitehouse Station, NJ.
• [43] Product Information. Hetlioz (tasimelteon). Vanda Pharmaceuticals Inc, Rockville, MD.
• [44] Product Information. Caplyta (lumateperone). Intra-Cellular Therapies, Inc., New York, NY.
• [45] Hill AG, Parry BR "Hypokalaemia following bowel cleansing with sodium phosphate." N Z Med J 109 (1996): 347. [PMID: 8862361]
• [46] Product Information. Zepzelca (lurbinectedin). Jazz Pharmaceuticals, Palo Alto, CA.
• [47] Product Information. Gavreto (pralsetinib). Blueprint Medicines Corporation, Cambridge, MA.
• [48] Product Information. Tabrecta (capmatinib). Novartis Pharmaceuticals, East Hanover, NJ.
• [49] Product Information. Calquence (acalabrutinib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
• [50] Product Information. Imbruvica (ibrutinib). Pharmacyclics Inc, Sunnyvale, CA.
• [51] Product Information. Iclusig (ponatinib). Ariad Pharmaceuticals Inc, Cambridge, MA.
• [52] Product Information. Koselugo (selumetinib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
• [53] Product Information. Ubrelvy (ubrogepant). Allergan Inc, Irvine, CA.
• [54] Product Information. Nurtec ODT (rimegepant). Biohaven Pharmaceuticals, New Haven, CT.
• [55] Product Information. Addyi (flibanserin). Sprout Pharmaceuticals, Raleigh, NC.
• [56] Product Information. Zejula (niraparib). Tesaro Inc., Waltham, MA.
• [57] Product Information. Xeglyze (abametapir topical). Dr. Reddy's Laboratories Inc, Upper Saddle River, NJ.
• [58] Product Information. Macrilen (macimorelin). Aeterna Zentaris, Charleston, SC.
• [59] Product Information. Nubeqa (darolutamide). Bayer HealthCare Pharmaceuticals Inc., Whippany, NJ.
• [60] Product Information. Rapaflo (silodosin). Watson Pharmaceuticals, Corona, CA.
• [61] Product Information. Torisel (temsirolimus). Wyeth-Ayerst Laboratories, Philadelphia, PA.
• [62] Product Information. Rinvoq (upadacitinib). AbbVie US LLC, North Chicago, IL.
• [63] Product Information. Stendra (avanafil). Vivus Inc, Mountain View, CA.
• [64] Product Information. Odomzo (sonidegib). Novartis Pharmaceuticals, East Hanover, NJ.
• [65] EMA. European Medicines Agency. European Union "EMA - List of medicines under additional monitoring.".